These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: RANTES/CCL5 polymorphisms as a risk factor for recurrent acute rejection.
    Author: Krüger B, Böger CA, Obed A, Farkas S, Hoffmann U, Banas B, Fischereder M, Krämer BK.
    Journal: Clin Transplant; 2007; 21(3):385-90. PubMed ID: 17488389.
    Abstract:
    BACKGROUND: The chemokine system plays an important role in the pathogenesis of acute rejection or atherosclerosis. Three polymorphisms in the promoter region of the chemokine RANTES (-403G/A, -28G/C, In1.1T/C) are associated with a different expression of this chemokine as well as the occurrence of cardiovascular disease. Therefore, we investigated the impact of these three polymorphisms on the outcome after renal transplantation. METHODS: In 261 patients receiving their first kidney transplant, we genotyped the RANTES promoter polymorphisms (-403G/A, -28G/C, In1.1T/C) by real-time PCR. RESULTS: For the RANTES -403G/A and for the intronic polymorphism In1.1T/C, we found a significantly higher rate of recurrent acute rejection episodes (-403G/A: 11.1 vs. 31.0%, In1.1T/C: 11.8 vs. 33.0%). For the overall rate of acute rejection, we observed no significant differences according to the RANTES promoter polymorphisms. The other tested variables (DGF, graft survival, renal function) were not associated with one of the three polymorphisms. CONCLUSION: Our data indicate a relevant role of RANTES in kidney transplantation, particularly for the occurrence of recurrent acute rejection. To clarify the role of the analysed polymorphisms for long-term survival, especially for the occurrence of cardiovascular events, larger studies in the future are needed.
    [Abstract] [Full Text] [Related] [New Search]